What Are the Barriers to Success When Implementing Care Pathways for ICH Patients?

July 12, 2022

ICH remains deadly and pathways matter but they aren't always what we need and barriers can be overcome with knowledge.

0 Comments

When Should We Consider Restarting Anticoagulation in DVT, PE and Afib Patients? What Should I Tell the Family To Be on the Look-Out for Once They Are Discharged?

February 1, 2022
When patients need anticoagulation but have had an ICH or large ischemic stroke, when do we restart anticoagulation? When, if ever, is it safe?  
0 Comments

Why Is the Extended Window Controversial and What Happened With the FDA?

September 7, 2021

Ever wonder why the FDA didn't approve the extended time window for tPA after ECASS3? Listen here to understand the discussion.

2 Comments

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

August 3, 2021
The association of genetic polymorphisms and P2Y12 inhibitors in regards to efficacy for patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. Drs. Deepak Bhatt of Brigham and Women’s Hospital and Natalie Kreitzer of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.
0 Comments

What Should All Physicians Know About Endovascular Stroke Care?

December 4, 2020
Endovascular stroke care is the criterion standard for LVO treatment, yet not everyone is fluent with data and techniques.  
0 Comments
RSS
12
Categories
More Entries